Particle size tailoring of ursolic acid nanosuspensions for improved anticancer activity by controlled antisolvent precipitation

Wang, Yancai; Song, Jun‐Yeob; Chow, Shing Fung; Chow, Albert H.L.; Zheng, Ying

doi:10.1016/j.ijpharm.2015.08.052

Cited by 37 publications

(22 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 In addition, UA is also limited in the treatment of cancer because of its insolubility, relatively short half-life, and low bioavailability. 8,9 Therefore, a convenient and safe delivery system urgently needs to be established to maximize the therapeutic efficacy at tumor sites while minimizing the side effects. 10 Application of nanotechnologies in oncology has greatly impacted cancer diagnosis and therapy in the past decade.…”

Section: Introductionmentioning

confidence: 99%

Self-assembled nanoparticles based on a carboxymethylcellulose–ursolic acid conjugate for anticancer combination therapy

Liu

et al. 2017

RSC Adv.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Self-assembled nanoparticles based on a carboxymethylcellulose–ursolic acid conjugate for anticancer combination therapy

Liu

et al. 2017

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…For instance, UA loaded in methoxy-poly(ethylene glycol)–polycaprolactone (mPEG–PCL) nanoparticles have shown enhanced cytotoxicity against gastric and liver cancer cell lines [28], [41]. UA nano-suspensions and nano-crystals have also demonstrated enhanced therapeutic effects over UA in solution [42], [43]. That efficacy was not improved in the present study may be attributable to a number of factors, including the relatively poor uptake of PMPC-PDPA polymersomes in fibroblasts relative to many other cell types and the use of galactose- instead of glucose- cell media, which results in lowered PMPC-PDPA polymersome uptake (Supp.…”

Section: Discussionmentioning

confidence: 99%

Rescue of mitochondrial function in -mutant fibroblasts using drug loaded PMPC-PDPA polymersomes and tubular polymersomes

Yealland

Battaglia²,

Bandmann

et al. 2016

Neuroscience Letters

View full text Add to dashboard Cite

HighlightsUrsolic acid and ursocholanic acid are efficiently encapsulated within PMPC-PDPA polymersomes of spherical or tubular morphology.PMPC-PDPA polymersomes spherical or tubular morphology are found to enter into parkin-mutant fibroblasts causing no deleterious effects.ATP levels are increased in parkin-mutant fibroblasts after incubation with ursolic or ursocholanic acid loaded PMPC-PDPA polymersomes.The efficacy of ursolic acid and ursochocholanic acid loaded PMPC-PDPA nanoparticles is similar to DMSO based formulations of the same compounds.

show abstract

“…Multi‐inlet vortex mixer (MIVM) as another antisolvent method is capable of providing more rapid and complete fluid micromixing to ensure instantaneous and homogenous nucleation while suppressing particle growth beyond the desired size with the aid of stabilizers . It was widely demonstrated that the MIVM can produce NPs with different sizes from micrometer to nanometer or even less than 100 nm, which is normally unachievable by milling or HPH methods. As shown in Figure (a), the flow rates of different streams, containing drug solvents, stabilizers, and antisolvents, were precisely controlled by digital syringe pump.…”

Section: Preparation Of Drug Ncsmentioning

confidence: 99%

Drug nanocrystals for cancer therapy

Miao

Yang

Feng

et al. 2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Drug nanocrystals (NCs) with fascinating physicochemical properties have attracted great attention in drug delivery. High drug-loading efficiency, great structural stability, steady dissolution, and long circulation time are a few examples of these properties, which makes drug NCs an excellent formulation for efficient cancer therapy. In the last two decades, there are a lot of hydrophobic or lipophilic drugs, such as paclitaxel (PTX), camptothecin (CPT), thymectacin, busulfan, cyclosporin A, 2-devinyl-2-(1-hexyloxyethyl) pyropheophorbide (HPPH), and so on, which have been formulated into drug NCs for cancer therapy. In this review, we summarized the recent advances in drug NCs-based cancer treatment. So far, there are main three methods to synthesize drug NCs, including top-down, bottom-up, and combination methods. The characterization methods of drug NCs were also elaborated. Furthermore, the applications and mechanisms of drug NCs were introduced by their administration routes. At the end, we gave a brief conclusion and discussed the future perspectives of drug NCs in cancer therapy. This article is categorized under: Implantable Materials and Surgical Technologies > Nanomaterials and Implants Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.

show abstract

Particle size tailoring of ursolic acid nanosuspensions for improved anticancer activity by controlled antisolvent precipitation

Cited by 37 publications

References 45 publications

Self-assembled nanoparticles based on a carboxymethylcellulose–ursolic acid conjugate for anticancer combination therapy

Self-assembled nanoparticles based on a carboxymethylcellulose–ursolic acid conjugate for anticancer combination therapy

Rescue of mitochondrial function in -mutant fibroblasts using drug loaded PMPC-PDPA polymersomes and tubular polymersomes

Drug nanocrystals for cancer therapy

Contact Info

Product

Resources

About